O'Neill Vincent 4
4 · BioXcel Therapeutics, Inc. · Filed Dec 17, 2024
Insider Transaction Report
Form 4
O'Neill Vincent
Other
Transactions
- Sale
Common Stock
2024-12-16$0.35/sh−165$58→ 19,957 total - Exercise/Conversion
Common Stock
2024-12-14+521→ 20,122 total - Exercise/Conversion
Restricted Stock Units
2024-12-14−521→ 2,606 total→ Common Stock (521 underlying)
Footnotes (3)
- [F1]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2023.
- [F3]On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.